PPARA and chronic thromboembolic pulmonary hypertension: In CTEPH, PPARα agonists effectively reduce TAFIα, which contributes to thrombus formation, vascular remodeling, and inflammation.480 In MCT-PAH, PPARα activation by fenofibrate alleviates oxidative stress and inflammation, downregulates NOX-1 expression, and preserves RV function.481